{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-026511","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.237078+00:00","generated_at":"2026-05-17T14:04:59.828615+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vaxart Q2 rev $39.7M; norovirus antibodies up 141%; COVID trial stopped at 5K enrolled","bullets":["Q2 2025 revenue $39.7M (vs $6.4M YoY); net loss $15.0M ($0.07/sh) vs $16.5M ($0.09/sh).","Positive norovirus Phase 1: second-gen constructs raised GI.1 blockers 141%, GII.4 94% vs first-gen.","COVID-19 Phase 2b enrollment halted Aug 5 at ~5,000 of planned 10,000; follow-up continues through late 2026.","Cash $26.3M; runway into Q1 2026; exploring partnerships and non-dilutive funding to extend.","Special meeting Sep 5 to vote on reverse stock split (1:5 to 1:20) for Nasdaq compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-026511","json":"https://secwatch.observer/filing/0001437749-25-026511.json","markdown":"https://secwatch.observer/filing/0001437749-25-026511.md","text":"https://secwatch.observer/filing/0001437749-25-026511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774925026511/0001437749-25-026511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774925026511/vxrt20250813_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:04:59.828615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}